Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 9069290 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Han J, et al. (1997) Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386, 296-9 9069290
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T293-p - MEF2C iso3 (human) ▲
Orthologous residues
MEF2C (human): T293‑p, MEF2C iso3 (human): T293‑p, MEF2C iso4 (human): T283‑p, MEF2C (mouse): T293‑p, MEF2C iso4 (mouse): T283‑p, MEF2C (rat): T304‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
 Disease tissue studied:  leukemia, acute myelogenous leukemia, lymphoma
 Relevant cell lines - cell types - tissues:  RAW 264 (macrophage), THP1 (myeloid), U-937 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE p38-alpha (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
Downstream Regulation
 Effect of modification (function):  activation
 Effect of modification (process):  transcription, altered

T300-p - MEF2C iso3 (human) ▲
Orthologous residues
MEF2C (human): T300‑p, MEF2C iso3 (human): T300‑p, MEF2C iso4 (human): T290‑p, MEF2C (mouse): T300‑p, MEF2C iso4 (mouse): T290‑p, MEF2C (rat): T311‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
 Disease tissue studied:  leukemia, acute myelogenous leukemia, lymphoma
 Relevant cell lines - cell types - tissues:  RAW 264 (macrophage), THP1 (myeloid), U-937 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE p38-alpha (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
Downstream Regulation
 Effect of modification (function):  activation
 Effect of modification (process):  transcription, altered

S387-p - MEF2C iso3 (human) ▲
Orthologous residues
MEF2C (human): S419‑p, MEF2C iso3 (human): S387‑p, MEF2C iso4 (human): S409‑p, MEF2C (mouse): S420‑p, MEF2C iso4 (mouse): S378‑p, MEF2C (rat): S441‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
 Disease tissue studied:  leukemia, acute myelogenous leukemia, lymphoma
 Relevant cell lines - cell types - tissues:  RAW 264 (macrophage), THP1 (myeloid), U-937 (myeloid)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE p38-alpha (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LPS increase
Downstream Regulation
 Effect of modification (function):  activation
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.